<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jgc41630" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Genet Couns</journal-id><journal-id journal-id-type="iso-abbrev">J Genet Couns</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">JGC4</journal-id><journal-title-group><journal-title>Journal of Genetic Counseling</journal-title></journal-title-group><issn pub-type="ppub">1059-7700</issn><issn pub-type="epub">1573-3599</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10087002</article-id><article-id pub-id-type="pmcid-ver">PMC10087002.1</article-id><article-id pub-id-type="pmcaid">10087002</article-id><article-id pub-id-type="pmcaiid">10087002</article-id><article-id pub-id-type="pmid">36036895</article-id><article-id pub-id-type="doi">10.1002/jgc4.1630</article-id><article-id pub-id-type="publisher-id">JGC41630</article-id><article-id pub-id-type="other">JOGC-D-21-00229</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Experience with a nurse&#8208;driven genetic counseling pathway of Italian women with uninformative <styled-content style="fixed-case" toggle="no">
<italic toggle="no">BRCA</italic>
</styled-content> test result</article-title><alt-title alt-title-type="left-running-head">Blondeaux et al.</alt-title></title-group><contrib-group><contrib id="jgc41630-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Blondeaux</surname><given-names initials="E">Eva</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9566-4579</contrib-id><xref rid="jgc41630-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jgc41630-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>evablondeaux@gmail.com</email></address></contrib><contrib id="jgc41630-cr-0002" contrib-type="author"><name name-style="western"><surname>Lambertini</surname><given-names initials="M">Matteo</given-names></name><xref rid="jgc41630-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="jgc41630-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jgc41630-cr-0003" contrib-type="author"><name name-style="western"><surname>Buzzatti</surname><given-names initials="G">Giulia</given-names></name><xref rid="jgc41630-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jgc41630-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jgc41630-cr-0004" contrib-type="author"><name name-style="western"><surname>Bruzzone</surname><given-names initials="C">Carla</given-names></name><xref rid="jgc41630-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jgc41630-cr-0005" contrib-type="author"><name name-style="western"><surname>Baraga</surname><given-names initials="M">Marina</given-names></name><xref rid="jgc41630-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jgc41630-cr-0006" contrib-type="author"><name name-style="western"><surname>Pisani</surname><given-names initials="R">Roberta</given-names></name><xref rid="jgc41630-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jgc41630-cr-0007" contrib-type="author"><name name-style="western"><surname>Del Mastro</surname><given-names initials="L">Lucia</given-names></name><xref rid="jgc41630-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jgc41630-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jgc41630-cr-0008" contrib-type="author"><name name-style="western"><surname>Pronzato</surname><given-names initials="P">Paolo</given-names></name><xref rid="jgc41630-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="jgc41630-cr-0009" contrib-type="author"><name name-style="western"><surname>Varesco</surname><given-names initials="L">Liliana</given-names></name><xref rid="jgc41630-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jgc41630-cr-0010" contrib-type="author"><name name-style="western"><surname>Bonelli</surname><given-names initials="L">Luigina</given-names></name><xref rid="jgc41630-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="jgc41630-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Breast Unit</named-content>
<institution>IRCCS Ospedale Policlinico San Martino</institution>
<city>Genoa</city>
<country country="IT">Italy</country>
</aff><aff id="jgc41630-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine</named-content>
<institution>University of Genova</institution>
<city>Genoa</city>
<country country="IT">Italy</country>
</aff><aff id="jgc41630-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Oncology, Clinica di Oncologia Medica</named-content>
<institution>IRCCS Ospedale Policlinico San Martino</institution>
<city>Genoa</city>
<country country="IT">Italy</country>
</aff><aff id="jgc41630-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Hereditary Cancer Unit</named-content>
<institution>IRCCS Ospedale Policlinico San Martino</institution>
<city>Genoa</city>
<country country="IT">Italy</country>
</aff><aff id="jgc41630-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Oncology, Medical Oncology 2</named-content>
<institution>IRCCS Ospedale Policlinico San Martino</institution>
<city>Genoa</city>
<country country="IT">Italy</country>
</aff><aff id="jgc41630-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Clinical Epidemiology Unit</named-content>
<institution>IRCCS Ospedale Policlinico San Martino</institution>
<city>Genoa</city>
<country country="IT">Italy</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Eva Blondeaux, IRCCS Ospedale Policlinico San Martino, University of Genova, Largo Rosanna Benzi 10, 16132 Genova, Italy.<break/>
Email: <email>evablondeaux@gmail.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2023</year></pub-date><volume>32</volume><issue seq="130">1</issue><issue-id pub-id-type="pmc-issue-id">433233</issue-id><issue-id pub-id-type="doi">10.1111/jgc4.v32.1</issue-id><fpage>140</fpage><lpage>152</lpage><history><date date-type="rev-recd"><day>05</day><month>8</month><year>2022</year></date><date date-type="received"><day>17</day><month>9</month><year>2021</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>12</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-12 05:10:11.730"><day>12</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2022 The Authors. <italic toggle="yes">Journal of Genetic Counseling</italic> published by Wiley Periodicals LLC on behalf of National Society of Genetic Counselors.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JGC4-32-140.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:JGC4-32-140.pdf"/><abstract><title>Abstract</title><p>Several models of genetic counseling have been proposed to tackle the increasing volume of individuals requiring access to <italic toggle="no">BRCA</italic> testing. Few data are available on patient experience and retention of information with nurse&#8208;driven genetic counseling. We evaluated the experience and retention of information in women with an uninformative <italic toggle="no">BRCA</italic> test result and who were not considered at high risk due to their personal/family history of cancer who underwent geneticist&#8208;supervised nurse&#8208;driven genetic counseling and who received their test result by phone. Women who received an uninformative <italic toggle="no">BRCA</italic> test result between May 2017 and September 2019 were administered a questionnaire exploring experience with genetic counseling and retention of information provided. Of 366 eligible women, 299 (273 breast cancer patients and 26 women without breast cancer) completed the interview. Overall, 280 women (93.6%) positively valued their experience with genetic counseling and 287 (96.0%) considered it helpful with 57.5% of them feeling reassured for themselves and their family. Information on the clinical implications of the test result was correctly retained and women acted accordingly. Overall, 252 women (87.8%) accurately reported their test result as normal/negative. Only 67 (22.4%) recognized that despite a normal <italic toggle="no">BRCA</italic> test result, a low probability of a hereditary syndrome remains. Most women showed a poor ability to estimate cancer risk in <italic toggle="no">BRCA</italic> mutation carriers and in the general population. Geneticist&#8208;supervised nurse&#8208;driven genetic counseling process for women with uninformative <italic toggle="no">BRCA</italic> test result is associated with a positive patient experience and an adequate retention of information concerning the management of their personal and familial cancer risk. The design and implementation of nurse&#8208;driven genetic counseling models may contribute to efficient and timely access to <italic toggle="no">BRCA</italic> genetic testing.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jgc41630-kwd-0001">genetic counseling</kwd><kwd id="jgc41630-kwd-0002">practice models</kwd><kwd id="jgc41630-kwd-0003">service delivery models</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Ministero della Salute
</institution><institution-id institution-id-type="doi">10.13039/501100003196</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="13"/><word-count count="6992"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.7 mode:remove_FC converted:11.04.2023</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="JGC41630-cit-2001"><string-name name-style="western"><surname>Blondeaux</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Lambertini</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Buzzatti</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Bruzzone</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Baraga</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Pisani</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Del Mastro</surname>,&#160;<given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Pronzato</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Varesco</surname>, <given-names>L.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Bonelli</surname>, <given-names>L.</given-names></string-name> (<year>2023</year>). <article-title>Experience with a nurse&#8208;driven genetic counseling pathway of Italian women with uninformative <styled-content style="fixed-case" toggle="no">
<italic toggle="no">BRCA</italic>
</styled-content> test result</article-title>. <source>Journal of Genetic Counseling</source>, <volume>32</volume>, <fpage>140</fpage>&#8211;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1002/jgc4.1630</pub-id><pub-id pub-id-type="pmid">36036895</pub-id><pub-id pub-id-type="pmcid">PMC10087002</pub-id></mixed-citation>
</p></notes></front><body id="jgc41630-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="jgc41630-blkfxd-0001" orientation="portrait"><sec id="jgc41630-sec-0002"><title>What is known about this topic</title><p>The demand for genetic counseling and <italic toggle="yes">BRCA</italic> testing has steadily increased in the last years. Thus, it is important to investigate new models of practice to ensure an appropriate and timely processing of these requests.</p></sec><sec id="jgc41630-sec-0003"><title>What this paper adds to the topic</title><p>Geneticist&#8208;supervised nurse&#8208;driven genetic counseling that includes a telephone disclosure of test result for women with an uninformative <italic toggle="yes">BRCA</italic> test is associated with a positive patient experience with genetic counseling and testing. This model can be time&#8208;saving for both working staff and patients.</p></sec></boxed-text>
</p><sec id="jgc41630-sec-0004"><label>1</label><title>INTRODUCTION</title><p>In recent years, the demand for <italic toggle="yes">BRCA</italic> testing has steadily increased. Several conditions co&#8208;occurred to prompt this growth: an improved awareness among the general population of the implications of having Hereditary Breast and Ovarian Cancer syndrome (HBOC) and the appropriate prevention actions (Raphael et al.,&#160;<xref rid="jgc41630-bib-0019" ref-type="bibr">2016</xref>), the usefulness of information on <italic toggle="yes">BRCA</italic> status for the surgical approach for breast cancer (BC) patients (risk&#8208;reducing mastectomy) (Domchek,&#160;<xref rid="jgc41630-bib-0008" ref-type="bibr">2019</xref>) and the approval of poly ADP&#8208;ribose polymerase (PARP) inhibitors for the medical treatment of <italic toggle="yes">BRCA</italic>&#8208;associated advanced/metastatic cancers (Buchtel et al.,&#160;<xref rid="jgc41630-bib-0005" ref-type="bibr">2018</xref>). A further increase in <italic toggle="yes">BRCA</italic> testing demand is expected as a recent trial demonstrated an improvement in invasive disease&#8208;free survival and in distant disease&#8208;free survival for human epidermal growth factor receptor 2 (HER2)&#8208;negative <italic toggle="yes">BRCA</italic>&#8208;mutated BC patients treated with adjuvant PARP inhibitors (Tutt et al.,&#160;<xref rid="jgc41630-bib-0024" ref-type="bibr">2021</xref>).</p><p>Traditionally, a genetic test is performed within a multistep in&#8208;person genetic counseling process provided by clinical genetics professionals, including clinical geneticists and qualified genetic counselors (Robson et al.,&#160;<xref rid="jgc41630-bib-0020" ref-type="bibr">2015</xref>; Skirton et al.,&#160;<xref rid="jgc41630-bib-0022" ref-type="bibr">2013</xref>; Trepanier et al.,&#160;<xref rid="jgc41630-bib-0023" ref-type="bibr">2004</xref>). At present, genetic counselors play an important role in mainstream genetic testing (Kentwell et al.,&#160;<xref rid="jgc41630-bib-0014" ref-type="bibr">2017</xref>). Except in the USA, UK, and few other countries where it is well established, the genetic counselor figure is continuing to develop worldwide with countries at different phases of progress (Abacan et al.,&#160;<xref rid="jgc41630-bib-0001" ref-type="bibr">2019</xref>). The successful implementation of genetic testing in genomic medicine will require flexibility on how genetic counselors are incorporated into the health care system (Ormond et al.,&#160;<xref rid="jgc41630-bib-0017" ref-type="bibr">2018</xref>).</p><p>To tackle the increasing volume of individuals requiring access to <italic toggle="yes">BRCA</italic> testing in due time, and to overcome barriers related to the complexity of the traditional multistep in&#8208;person genetic counseling and to the shortage of genetics professionals, utilization of several alternative genetic counseling service models for HBOC identification have been proposed (telephone counseling, tele&#8208;genetics, group counseling) and professional staff with different expertise (genetics or nongenetic health professionals) have been involved (Buchanan et al.,&#160;<xref rid="jgc41630-bib-0004" ref-type="bibr">2016</xref>).</p><p>In Italy, the genetic counselor profession is not recognized and genetic units offering genetic counseling for cancer predisposing syndromes rely on genetics specialists, i.e., medical doctors or biologists with a specialty in Medical Genetics. When <italic toggle="yes">BRCA</italic> testing was first introduced in clinical practice for prevention, an oncologist&#8208; and psychologist&#8208;driven genetic counseling model was introduced as an alternative model to traditional genetic counseling (Contegiacomo et al.,&#160;<xref rid="jgc41630-bib-0006" ref-type="bibr">2004</xref>). Recently, an oncologist&#8208;driven &#8220;mini&#8208;counseling&#8221; model was proposed for ovarian cancer (OC) patients who can benefit from genetic testing for therapeutic purposes. In this model, a trained oncologist provides patients with appropriate information on the genetic aspects associated with the test results, collects the informed consent, prescribes the <italic toggle="yes">BRCA</italic> test, and gives back the result to the patient (Gori et al.,&#160;<xref rid="jgc41630-bib-0010" ref-type="bibr">2019</xref>).</p><p>At present, although many <italic toggle="yes">BRCA</italic> testing paths have been proposed worldwide, several questions about the optimal testing strategy remain unanswered. As models of genetic counseling evolve, multidisciplinary teams of professionals (e.g., clinical geneticists, medical oncologists, surgeons, gynecologists, etc) will be involved in the process and flexible models that can be adapted to the preferences of the patients about the way they receive information and counseling will be designed (Hoogerbrugge &amp; Jongmans,&#160;<xref rid="jgc41630-bib-0011" ref-type="bibr">2016</xref>; McCuaig et al.,&#160;<xref rid="jgc41630-bib-0016" ref-type="bibr">2018</xref>). Ideally, the two components of the <italic toggle="yes">BRCA</italic> testing process (information and counseling) should be tiered according to the preferences and needs of different groups of individuals, balancing the level of information and counseling useful to take informed decisions with the possible harms of unnecessary deep discussion of an HBOC diagnosis in the absence of high risk of having the condition (e.g., increasing fear of breast and ovarian cancer for healthy close relatives in the pretest phase or in the presence of an uninformative test result). Flexible models may address this problem by creating &#8220;light&#8221; pathways (i.e., less psychologically demanding for patients and less resource&#8208;intensive for the unit providing genetic counseling) in addition to classical multiple&#8208;step in&#8208;person pathways involving expert genetics counselors (Hoogerbrugge &amp; Jongmans,&#160;<xref rid="jgc41630-bib-0011" ref-type="bibr">2016</xref>).</p><p>At the Unit of Hereditary Cancers (UHC) of the IRCCS Ospedale Policlinico San Martino in Genoa (Italy), the high increase in <italic toggle="yes">BRCA</italic> testing demand led us to find a way to provide timely processing of these requests. Thus, a geneticist&#8208;supervised nurse&#8208;driven pathway (from the contact with the unit to the disclosure of the test result) has been implemented for individuals with an uninformative <italic toggle="yes">BRCA</italic> test result who are not considered at high risk due to their personal/family history of cancer.</p><p>The aim of the present study was to evaluate the experience and retention of information following genetic counseling for a group of women who had an uninformative <italic toggle="yes">BRCA</italic> test result that was disclosed by telephone using a nurse&#8208;driven practice.</p></sec><sec sec-type="methods" id="jgc41630-sec-0005"><label>2</label><title>METHODS</title><p>This is an observational study that investigated the experience and retention of information in a group of women enrolled in the Ligurian <italic toggle="yes">BRCA</italic> Registry who had genetic counseling and testing for suspected HBOC at the UHC, had an uninformative <italic toggle="yes">BRCA</italic> test result (i.e., no pathogenic variants, including variant of unknown significance [VUS]), were not considered at high risk based on their personal/family history of cancer, and received the test result on phone by a nurse (description of the Ligurian <italic toggle="yes">BRCA</italic> registry is reported in <xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>). Data were derived from a telephone survey conducted by the nurse staff of the UHC after a temporal window of at least 1&#8201;year from <italic toggle="yes">BRCA</italic> test disclosure. Phone interviews were carried out from April 22nd, 2020, to November 20th, 2020.</p><sec id="jgc41630-sec-0006"><label>2.1</label><title>Participants</title><p>Eligible women were aged 18&#8211;65&#8201;years, had their <italic toggle="yes">BRCA</italic> test performed between May 5, 2017, and September 30, 2019, had an uninformative <italic toggle="yes">BRCA</italic> test result not associated with high risk or complicated pretest situation, and had received their test result by phone. Women with metastatic BC or OC, who had not undergone their genetic counseling at the UHC, and who did not speak fluent Italian were excluded.</p><p>General characteristics, recall, experience, and retention of information were collected during the phone interview.</p></sec><sec id="jgc41630-sec-0007"><label>2.2</label><title>Nurse&#8208;driven genetic counseling for <styled-content style="fixed-case" toggle="no">HBOC</styled-content> identification</title><p>The staff of the UHC is comprised of a clinical geneticist and three nurses. One nurse is certified by the European Board of Medical Genetics (EBMG) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebmg.eu/408.0.html" ext-link-type="uri">https://www.ebmg.eu/408.0.html</ext-link>) (i.e., genetics nurse), while the other two were trained during the weekly unit staff meetings and through practical experience (i.e., oncology nurses).</p><p>The genetic counseling process is described in Box&#160;<xref rid="jgc41630-fea-0001" ref-type="boxed-text">1</xref>.</p><boxed-text position="float" content-type="BOX" id="jgc41630-fea-0001" orientation="portrait"><label>BOX 1</label><caption><title>Description of the genetic counseling pathway for HBOC syndrome identification</title></caption><p>
<table-wrap position="anchor" id="jats-table-wrap-1" orientation="portrait"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">New request</td><td align="left" valign="top" rowspan="1" colspan="1">A physician (a specialist or a primary care physician) or directly a patient to whom our contacts have been provided can make a request for evaluation. To start a new request, people are invited to leave a message on an answering machine or to send an e&#8208;mail</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">First contact by telephone triage</td><td align="left" valign="top" rowspan="1" colspan="1">An oncology nurse calls the patient back in a few days to: (a) explore the expectation of the person; (b) assess eligibility for <italic toggle="yes">BRCA</italic> testing by collecting personal history and building a three&#8208;generation oncological pedigree; (c) give general information about the genetic counseling process and <italic toggle="yes">BRCA</italic> testing. Length of the phone call: 25&#8211;45&#8201;min</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triage staff meeting (weekly)</td><td align="left" valign="top" rowspan="1" colspan="1">The nurses discuss all cases with the clinical geneticist and emerging issues potentially relevant to the subsequent precounseling phase are explored. The discussion focuses on the appropriate application of testing criteria (e.g., limitations due to family structure, quality of available information) and the evaluation of psychosocial issues (i.e., how to help the individuals to cope with genetic testing choice/result). If HBOC is suspected according to regional guidelines (Bonelli et al.,&#160;<xref rid="jgc41630-bib-0003" ref-type="bibr">2021</xref>) or the test result could be beneficial for medical or surgical treatment, an appointment for in&#8208;person pretest counseling is offered</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pretest counseling (in&#8208;person)</td><td align="left" valign="top" rowspan="1" colspan="1">The genetics nurse explains <italic toggle="yes">BRCA</italic>&#8208;associated cancer risk, implications of a positive <italic toggle="yes">BRCA</italic> test for the counselee and for family members, and prevention options. The educational content of the intervention focuses on the significance of a positive <italic toggle="yes">BRCA</italic> genetic testing for the patient and his/her family (options for cancer risk reduction, the transmission mode of the genetic variant, if any) and information is given verbally without the support of educational tools. Cancer risk information is verbally provided in a qualitative form (&#8220;high risk&#8221; vs. &#8220;population risk&#8221;). Support for the decision about testing is given by using a shared decision&#8208;making model. People who accept to undergo <italic toggle="yes">BRCA</italic> testing provide a written consent and a peripheral blood sample. Length of the pretest counseling: 30&#8211;50&#8201;min. No written material is given to the patient. If needed, additional professional support is arranged with a psychologist</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">BRCA</italic> test analysis</td><td align="left" valign="top" rowspan="1" colspan="1">The genetic test is performed by Next Generation Sequencing and Multiplex Ligation&#8208;dependent Probe Amplification analyses of the <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> genes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">BRCA</italic> test result staff meeting (weekly)</td><td align="left" valign="top" rowspan="1" colspan="1">The <italic toggle="yes">BRCA</italic> test result is discussed with the clinical geneticist to decide the appropriate communication modality according to the test result and to case&#8208;specific clinical and psychosocial characteristics</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Post&#8208;test counseling</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">(A) In&#8208;person</td><td align="left" valign="top" rowspan="1" colspan="1">People with a <italic toggle="yes">BRCA</italic> pathogenic/likely pathogenic variant and those with uninformative <italic toggle="yes">BRCA</italic> test who are considered HBOC&#8208;equivalent or with a complicated pretest situation (e.g., family history patterns deserving further testing, patients considering preventive surgery in the absence of an HBOC diagnosis) have post&#8208;test counseling with the clinical geneticist. Length of post&#8208;test counseling: 45&#8211;80&#8201;min. Individuals also receive a letter summarizing the information given</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">(B) Telephone call and standard letter</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Uninformative <italic toggle="yes">BRCA</italic> test results (i.e., no pathogenic variants, including a variant of unknown significance) not associated with the above&#8208;mentioned circumstances are disclosed with a phone call by a nurse unless the person prefers to come to the UHC for in&#8208;person communication. During the telephone conversation, the nurse gives the following key messages: (i) your test did not show the presence of a situation of hereditary predisposition to cancer associated with <italic toggle="yes">BRCA</italic> mutations; (ii) your test result and your personal/family history of cancer do not suggest to adopt high&#8208;risk prevention measures; (iii) the test has limitations, other tests may be available in the future. Length of the phone call: 10&#8211;20&#8201;min</p>
<p>Individuals also receive a standard letter stating the same messages; if a VUS is detected, its implications are reported (<xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>)</p>
</td></tr></tbody></table></table-wrap>
</p><sec id="jgc41630-sec-0009"><p>
<italic toggle="yes">Note</italic>: Genetic counseling and testing are offered as National Health Service interventions free&#8208;of&#8208;charge to cancer patients and with the payment of a small fee to healthy individuals.</p></sec></boxed-text><p>According to our model, the genetics nurse is involved in the in&#8208;person pretest counseling while the oncology nurses are involved in the triage phase. Both the oncology nurses and the genetics nurse take part in the telephone communication of uninformative test results to patients not considered at high risk for personal/family history. Due to staff limitations, exceptions to this rule may occur (e.g., holidays, illness) to maintain service activities.</p></sec><sec id="jgc41630-sec-0010"><label>2.3</label><title>Survey</title><p>To collect information about patients' experiences with the genetic counseling model and their recall of information an ad hoc questionnaire was developed through the following phases: (1) literature review on HBOC genetic counseling models and particularly on nurse&#8208;driven genetic counseling; (2) identification of the main items of interest of the present study (i.e., experience with the genetic counseling process and retention of information provided during genetic counseling); (3) preparation of a preliminary draft (two authors L.V. and L.B.); (4) revision of the draft with the staff nurses to check for completeness, comprehension, and redundancy; (5) preparation of the final version of the questionnaire (<xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>). The questionnaire consisted of three sections; questions included closed answers with the possibility to add free text comments:
<list list-type="bullet" id="jgc41630-list-0001"><list-item id="jgc41630-li-0001"><p>Section 1. Motivation and recall&#8212;four questions: (1) perceived time elapsed from test disclosure; (2) referral to genetic counseling; (3) reason for testing; (4) test result</p></list-item><list-item id="jgc41630-li-0002"><p>Section 2. Self&#8208;reported outcomes&#8212;six questions: (1) helpfulness of genetic counseling, (2&#8211;3) changes in medical check&#8208;ups of the interviewee and of her close family members; (4) personal experience with genetic counseling; (5) personal experience with telephone contact; (6) sharing the test result.</p></list-item><list-item id="jgc41630-li-0003"><p>Section 3. Knowledge&#8212;five questions: (1) meaning of a normal <italic toggle="yes">BRCA</italic> test; (2) BC risk among <italic toggle="yes">BRCA</italic> mutation carriers and in the general population; (3) OC risk among <italic toggle="yes">BRCA</italic> mutation carriers and in the general population; (4) risk of other cancers among women carrying a <italic toggle="yes">BRCA</italic> pathogenic variant; (5) cancer risks of men carrying a <italic toggle="yes">BRCA</italic> pathogenic variant.</p></list-item></list>
</p><p>The nurses administered the questionnaire by phone to the selected women and up to three calls were allocated for each woman.</p><p>No specific informed consent was required for this survey as, by providing a written consent for the inclusion in the Ligurian <italic toggle="yes">BRCA</italic> registry, individuals accepted to be contacted to update their personal history, and to be invited to participate in prevention programs and other initiatives (Ligurian Ethics Committee approval n. 002REG2017, <xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>).</p></sec><sec id="jgc41630-sec-0011"><label>2.4</label><title>
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">BRCA</italic>
</styled-content>&#8208;associated activity of the <styled-content style="fixed-case" toggle="no">UHC</styled-content>
</title><p>The activity of the UHC associated with the provision of <italic toggle="yes">BRCA</italic> testing during the last 5&#8201;years (2017&#8211;2021) was evaluated to estimate the benefit of our model in terms of efficiency.</p><p>The following information was retrieved from the clinical database: number of <italic toggle="yes">BRCA</italic> test provided, test result and modalities of test result communication (in&#8208;person or on&#8208;telephone). The post&#8208;test disclosure of uninformative <italic toggle="yes">BRCA</italic> test is performed by a nurse and takes around 15&#8201;min (range 10&#8211;20&#8201;min) for a telephone test disclosure and around 25&#8201;min (20&#8211;30&#8201;min) for an in&#8208;person test disclosure (Bonelli et al.,&#160;<xref rid="jgc41630-bib-0003" ref-type="bibr">2021</xref>).</p></sec><sec id="jgc41630-sec-0012"><label>2.5</label><title>Data analysis</title><p>Analyses are descriptive. Counts and percentages were used for categorical variables, whereas median and range were used to summarize continuous variables. The chi&#8208;squared test and the Mann&#8211;Whitney <italic toggle="yes">U</italic> test were used to compare differences among categorical and continuous variables, respectively.</p><p>Open answers provided by the women were grouped according to their meaning (details are provided in <xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>). Regarding patient experience, the last three points of the 5&#8208;point Likert scale (i.e., enough, much, very much) of responses to question 2.1 (Were genetic counseling and <italic toggle="yes">BRCA</italic> testing somehow helpful to you and your family?) and the first point of the 5&#8208;point Likert scale (i.e., not at all) of responses to question 2.5 (Did you feel uncomfortable because the first contact with our center took place by phone?) were considered suggestive of a positive patient experience. Analyses were performed according to the presence of the history of BC. Statistical analyses were performed using SAS 9.4 (SAS Institute).</p></sec></sec><sec sec-type="results" id="jgc41630-sec-0013"><label>3</label><title>RESULTS</title><p>From May 2017 to September 2019, 908 individuals were enrolled in the Ligurian <italic toggle="yes">BRCA</italic> registry, and 366 of them met the eligibility criteria for the interview (335 BC patients and 31 women without BC). Among them, 43 were not traced, 17 refused to participate and seven did not complete the interview, no statistically significant differences were observed between responders and nonresponders (Figure&#160;<xref rid="jgc41630-fig-0001" ref-type="fig">1</xref>). Main reasons for refusal were lack of time for the interview (<italic toggle="yes">n</italic>&#160;=&#160;11) and no interest in the study (<italic toggle="yes">n</italic>&#160;=&#160;4).</p><fig position="float" fig-type="FIGURE" id="jgc41630-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Women participating in the study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="JGC4-32-140-g001.jpg"/></fig><sec id="jgc41630-sec-0014"><label>3.1</label><title>Characteristics of study participants</title><p>Overall, 299 women (273 BC patients and 26 women without BC) completed the interview and were included in the study. The main characteristics of the study population are reported in Table&#160;<xref rid="jgc41630-tbl-0001" ref-type="table">1</xref>. Breast cancer patients and women without BC had similar characteristics except for menopausal status (BC patients were more frequently postmenopausal and menopause was secondary to oncological medical treatments for 120 BC patients [44.0%]). No <italic toggle="yes">BRCA</italic> variant was detected in 262 of 299 women (87.6%), 30 had a VUS (10.0%) and seven (2.3%) had a likely benign variant.</p><table-wrap position="float" id="jgc41630-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Characteristics of women who completed the phone interview with the nurse</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Breast cancer patients (<italic toggle="yes">N</italic>&#160;=&#160;273)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Women without breast cancer (<italic toggle="yes">N</italic>&#160;=&#160;26)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> Value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at <italic toggle="yes">BRCA</italic> testing (median. range)</td><td align="char" valign="top" rowspan="1" colspan="1">49 (27&#8211;64)</td><td align="char" valign="top" rowspan="1" colspan="1">46.5 (30&#8211;64)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at questionnaire (median. range)</td><td align="char" valign="top" rowspan="1" colspan="1">50 (30&#8211;65)</td><td align="char" valign="top" rowspan="1" colspan="1">47 (31&#8211;65)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at menarche (median. range)</td><td align="char" valign="top" rowspan="1" colspan="1">12 (8&#8211;17)</td><td align="char" valign="top" rowspan="1" colspan="1">12.5 (9&#8211;14)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.56</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">No. of children</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0</td><td align="char" valign="top" rowspan="1" colspan="1">58 (21.2)</td><td align="char" valign="top" rowspan="1" colspan="1">6 (23.1)</td><td align="char" char="." rowspan="4" valign="top" colspan="1">0.14</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td><td align="char" valign="top" rowspan="1" colspan="1">93 (34.1)</td><td align="char" valign="top" rowspan="1" colspan="1">5 (19.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2+</td><td align="char" valign="top" rowspan="1" colspan="1">117 (42.9)</td><td align="char" valign="top" rowspan="1" colspan="1">13 (50.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" valign="top" rowspan="1" colspan="1">5 (1.8)</td><td align="char" valign="top" rowspan="1" colspan="1">2 (7.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Use of contraceptive pill</td><td align="char" valign="top" rowspan="1" colspan="1">182 (66.7)</td><td align="char" valign="top" rowspan="1" colspan="1">16 (61.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.59</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Menopausal status</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Premenopause</td><td align="char" valign="top" rowspan="1" colspan="1">46 (16.8)</td><td align="char" valign="top" rowspan="1" colspan="1">13 (50.0)</td><td align="char" char="." rowspan="3" valign="top" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Postmenopause</td><td align="char" valign="top" rowspan="1" colspan="1">224 (82.1)</td><td align="char" valign="top" rowspan="1" colspan="1">12 (46.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" valign="top" rowspan="1" colspan="1">3 (1.1)</td><td align="char" valign="top" rowspan="1" colspan="1">1 (3.8)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Smoking habits</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Never smoker</td><td align="char" valign="top" rowspan="1" colspan="1">173 (63.4)</td><td align="char" valign="top" rowspan="1" colspan="1">15 (57.7)</td><td align="char" char="." rowspan="4" valign="top" colspan="1">0.72</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Current smoker</td><td align="char" valign="top" rowspan="1" colspan="1">39 (14.3)</td><td align="char" valign="top" rowspan="1" colspan="1">3 (11.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Former smoker</td><td align="char" valign="top" rowspan="1" colspan="1">59 (21.6)</td><td align="char" valign="top" rowspan="1" colspan="1">8 (30.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td align="char" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Educational level</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#8804;8&#8201;years</td><td align="char" valign="top" rowspan="1" colspan="1">57 (20.9)</td><td align="char" valign="top" rowspan="1" colspan="1">1 (3.8)</td><td align="char" char="." rowspan="3" valign="top" colspan="1">0.11</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">9&#8211;13&#8201;years</td><td align="char" valign="top" rowspan="1" colspan="1">146 (53.5)</td><td align="char" valign="top" rowspan="1" colspan="1">17 (65.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&gt;13&#8201;years</td><td align="char" valign="top" rowspan="1" colspan="1">70 (25.6)</td><td align="char" valign="top" rowspan="1" colspan="1">8 (30.8)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Year of <italic toggle="yes">BRCA</italic> testing</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2017</td><td align="char" valign="top" rowspan="1" colspan="1">44 (16.1)</td><td align="char" valign="top" rowspan="1" colspan="1">2 (7.7)</td><td align="char" char="." rowspan="3" valign="top" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2018</td><td align="char" valign="top" rowspan="1" colspan="1">118 (43.2)</td><td align="char" valign="top" rowspan="1" colspan="1">3 (11.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2019</td><td align="char" valign="top" rowspan="1" colspan="1">111 (40.7)</td><td align="char" valign="top" rowspan="1" colspan="1">21 (80.8)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Clinical reasons for <italic toggle="yes">BRCA</italic> testing</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Prevention</td><td align="char" valign="top" rowspan="1" colspan="1">192 (70.3)</td><td align="char" valign="top" rowspan="1" colspan="1">26 (100.0)</td><td align="char" char="." rowspan="2" valign="top" colspan="1">N.A.</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Medical/surgical treatment</td><td align="char" valign="top" rowspan="1" colspan="1">81 (29.7)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">
<italic toggle="yes">BRCA</italic> 1&#8211;2 test result</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No <italic toggle="yes">BRCA</italic> variant</td><td align="char" valign="top" rowspan="1" colspan="1">236 (86.4)</td><td align="char" valign="top" rowspan="1" colspan="1">26 (100.0)</td><td align="char" char="." rowspan="3" valign="top" colspan="1">0.13</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Variant of unknown significance</td><td align="char" valign="top" rowspan="1" colspan="1">30 (11.0)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Likely benign variant</td><td align="char" valign="top" rowspan="1" colspan="1">7 (2.6)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table><table-wrap-foot id="jgc41630-ntgp-0001"><fn id="jgc41630-note-0001"><p>Abbreviation: N.A., not applicable.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jgc41630-sec-0015"><label>3.2</label><title>Survey</title><p>Information on which nurse communicated the test result and/or interviewed each woman was available for 276 of 299 women (92.3%) (Table <xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">S1</xref>). The majority of the phone results disclosures were made by the oncology nurses (229 of 276, 83.0%). Around 30% of women (84 of 276, 30.4%) were interviewed by the same nurse who communicated their test result to them.</p><p>Median duration of phone interviews was 12&#8201;min (IQR: 10&#8211;15&#8201;min). Median interval between <italic toggle="yes">BRCA</italic> test and phone interview was 19.0&#160;months (range 12.0&#8211;35.0&#160;months).</p></sec><sec id="jgc41630-sec-0016"><label>3.3</label><title>Motivation and recall</title><p>The majority of women properly reported the time of their genetic counseling appointment (Table&#160;<xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">S2</xref>). There was no association between time elapsed since results disclosure and the ability to accurately recall the <italic toggle="yes">BRCA</italic> test result (Table&#160;<xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">S3</xref>).</p><p>Regarding motivation for undertaking genetic counseling, nearly 40% of BC patients (107 of 273) and 70% of women without BC (18 of 26) reported a family history of BC while few women reported a family history of OC (Table&#160;<xref rid="jgc41630-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="jgc41630-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Motivation and recall</p></caption><table frame="hsides" rules="all"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Survey questions</th><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Total</th><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Breast cancer patients</th><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Women without breast cancer</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic> (%)</th><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic> (%)</th><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic> (%)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">299 (100.0)</th><th align="left" valign="bottom" rowspan="1" colspan="1">273 (100.0)</th><th align="left" valign="bottom" rowspan="1" colspan="1">26 (100.0)</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" rowspan="1">1.2 Who referred you to genetic counseling?<xref rid="jgc41630-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Oncologist</td><td align="char" valign="top" rowspan="1" colspan="1">231 (77.3)</td><td align="char" valign="top" rowspan="1" colspan="1">227 (83.1)</td><td align="char" valign="top" rowspan="1" colspan="1">4 (15.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Gynecologist</td><td align="char" valign="top" rowspan="1" colspan="1">18 (6.0)</td><td align="char" valign="top" rowspan="1" colspan="1">9 (3.3)</td><td align="char" valign="top" rowspan="1" colspan="1">9 (34.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Radiologist</td><td align="char" valign="top" rowspan="1" colspan="1">16 (5.5)</td><td align="char" valign="top" rowspan="1" colspan="1">14 (5.1)</td><td align="char" valign="top" rowspan="1" colspan="1">2 (7.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">General practitioner</td><td align="char" valign="top" rowspan="1" colspan="1">8 (2.7)</td><td align="char" valign="top" rowspan="1" colspan="1">4 (1.5)</td><td align="char" valign="top" rowspan="1" colspan="1">4 (15.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Family</td><td align="char" valign="top" rowspan="1" colspan="1">6 (2.0)</td><td align="char" valign="top" rowspan="1" colspan="1">3 (1.1)</td><td align="char" valign="top" rowspan="1" colspan="1">3 (11.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Surgeon</td><td align="char" valign="top" rowspan="1" colspan="1">15 (5.0)</td><td align="char" valign="top" rowspan="1" colspan="1">14 (5.1)</td><td align="char" valign="top" rowspan="1" colspan="1">1 (3.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Self&#8208;referral</td><td align="char" valign="top" rowspan="1" colspan="1">18 (6.0)</td><td align="char" valign="top" rowspan="1" colspan="1">14 (5.1)</td><td align="char" valign="top" rowspan="1" colspan="1">4 (15.4)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">1.3 Do you remember why you underwent the <italic toggle="yes">BRCA</italic> test?</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">I was operated on for a cancer</td><td align="char" valign="top" rowspan="1" colspan="1">156 (52.2)</td><td align="char" valign="top" rowspan="1" colspan="1">156 (57.1)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">There are cases of breast cancer in my family</td><td align="char" valign="top" rowspan="1" colspan="1">125 (41.8)</td><td align="char" valign="top" rowspan="1" colspan="1">107 (39.2)</td><td align="char" valign="top" rowspan="1" colspan="1">18 (69.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">There are cases of ovarian cancer in my family</td><td align="char" valign="top" rowspan="1" colspan="1">1 (0.3)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" valign="top" rowspan="1" colspan="1">1 (3.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">There are cases of breast and ovarian cancer in my family</td><td align="char" valign="top" rowspan="1" colspan="1">15 (5.0)</td><td align="char" valign="top" rowspan="1" colspan="1">9 (3.3)</td><td align="char" valign="top" rowspan="1" colspan="1">6 (23.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td align="char" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="char" valign="top" rowspan="1" colspan="1">1 (3.8)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">1.4 Do you remember which was the result of your <italic toggle="yes">BRCA</italic> test?</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="char" valign="top" rowspan="1" colspan="1">12 (4.0)</td><td align="char" valign="top" rowspan="1" colspan="1">11 (4.0)</td><td align="char" valign="top" rowspan="1" colspan="1">1 (3.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" valign="top" rowspan="1" colspan="1">287 (96.0)</td><td align="char" valign="top" rowspan="1" colspan="1">262 (96.0)</td><td align="char" valign="top" rowspan="1" colspan="1">25 (96.2)</td></tr><tr><td style="padding-left:10%" colspan="4" align="left" valign="top" rowspan="1">If yes, can you briefly tell me, with your own words, what you remember about the test result?<xref rid="jgc41630-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Negative/normal</td><td align="char" valign="top" rowspan="1" colspan="1">252 (87.8)</td><td align="char" valign="top" rowspan="1" colspan="1">227 (86.6)</td><td align="char" valign="top" rowspan="1" colspan="1">25 (100.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Not completely negative (a variant detected)</td><td align="char" valign="top" rowspan="1" colspan="1">14 (4.9)</td><td align="char" valign="top" rowspan="1" colspan="1">14 (5.3)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">No inheritance</td><td align="char" valign="top" rowspan="1" colspan="1">18 (6.3)</td><td align="char" valign="top" rowspan="1" colspan="1">18 (6.9)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Negative but to be repeated in the future</td><td align="char" valign="top" rowspan="1" colspan="1">3 (1.0)</td><td align="char" valign="top" rowspan="1" colspan="1">3 (1.1)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" colspan="4" align="left" valign="top" rowspan="1">If yes, which of the following answers correspond to your <italic toggle="yes">BRCA</italic> test result?</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">No variant</td><td align="char" valign="top" rowspan="1" colspan="1">174 (60.6)</td><td align="char" valign="top" rowspan="1" colspan="1">158 (60.3)</td><td align="char" valign="top" rowspan="1" colspan="1">16 (64.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Variant of little/null significance</td><td align="char" valign="top" rowspan="1" colspan="1">4 (1.4)</td><td align="char" valign="top" rowspan="1" colspan="1">4 (1.5)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Variant likely benign</td><td align="char" valign="top" rowspan="1" colspan="1">3 (1.0)</td><td align="char" valign="top" rowspan="1" colspan="1">3 (1.1)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Variant of uncertain significance</td><td align="char" valign="top" rowspan="1" colspan="1">13 (4.5)</td><td align="char" valign="top" rowspan="1" colspan="1">13 (5.0)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Pathogenic or likely pathogenic variant</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Don't know</td><td align="char" valign="top" rowspan="1" colspan="1">83 (28.9)</td><td align="char" valign="top" rowspan="1" colspan="1">74 (28.2)</td><td align="char" valign="top" rowspan="1" colspan="1">9 (36.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" valign="top" rowspan="1" colspan="1">10 (3.5)</td><td align="char" valign="top" rowspan="1" colspan="1">10 (3.8)</td><td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table><table-wrap-foot id="jgc41630-ntgp-0002"><fn id="jgc41630-note-0002"><label>
<sup>a</sup>
</label><p>More referring persons could be reported.</p></fn><fn id="jgc41630-note-0003"><label>
<sup>b</sup>
</label><p>Open answers were categorized after collecting all questionnaires.</p></fn></table-wrap-foot></table-wrap><p>Among women referred to genetic counseling by a physician, the majority of BC patients were referred by an oncologist (227 of 250, 90.8%) while women without BC were referred by many different professionals (Table&#160;<xref rid="jgc41630-tbl-0002" ref-type="table">2</xref>). Nearly all BC patients referred by an oncologist spoke with him/her about the test result (96.9%). Similarly, the majority of women without BC (&gt;80%) spoke with the referring physician (Table&#160;<xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">S4</xref>). After receiving the test result, most women shared it with more than one professional (Table&#160;<xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">S5</xref>) and the majority shared it with family members (185 [68.7%] of 273&#8201;BC patients and 17 [65.4%] of 26 women without BC).</p><p>Overall, 287 of 299 women (96.0%) stated that they remembered the results of their <italic toggle="yes">BRCA</italic> test (Table&#160;<xref rid="jgc41630-tbl-0002" ref-type="table">2</xref>). When asked to say the result in their own word, 252 of them (87.8%) reported their result as &#8220;negative/normal&#8221; and none described the test result as suggestive of the presence of an inherited cancer syndrome. In addition, women who remembered the result of the test were invited to assign their test result to one of five proposed categories (no variant, variant of little/null significance, variant likely benign, variant of uncertain significance, pathogenic or likely pathogenic variant &#8208; corresponding to the words used in the laboratory report): 194 women (64.8%) did so, and none reported the presence of a pathogenic variant. The categorization provided by the women was compared with the laboratory <italic toggle="yes">BRCA</italic> result and 181 of 194 women (93.3%) remembered the exact category of their test result. A test with no variant was correctly reported by 167 of 174 women (151 of 158&#8201;BC patients and 16 of 16 women without BC); a VUS was correctly reported by 13 of 21&#8201;BC patients, and a likely benign variant was correctly reported by one of five BC patients (Table&#160;<xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">S6</xref>).</p></sec><sec id="jgc41630-sec-0017"><label>3.4</label><title>Self&#8208;reported outcomes</title><p>The personal experience of women interviewed is reported in Table&#160;<xref rid="jgc41630-tbl-0003" ref-type="table">3</xref>.</p><table-wrap position="float" id="jgc41630-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Self&#8208;reported outcomes and knowledge</p></caption><table frame="hsides" rules="all"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Survey questions</th><th align="left" valign="bottom" rowspan="1" colspan="1">All women (<italic toggle="yes">N</italic>&#160;=&#160;299)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Breast cancer patients (<italic toggle="yes">N</italic>&#160;=&#160;273)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Women without breast cancer (<italic toggle="yes">N</italic>&#160;=&#160;26)</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" rowspan="1">2.1 Were genetic counseling and <italic toggle="yes">BRCA</italic> testing somehow helpful to you and your family?</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not at all</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">A little</td><td align="left" valign="top" rowspan="1" colspan="1">7 (2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Enough</td><td align="left" valign="top" rowspan="1" colspan="1">83 (27.8)</td><td align="left" valign="top" rowspan="1" colspan="1">76 (27.8)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (26.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Much</td><td align="left" valign="top" rowspan="1" colspan="1">162 (54.2)</td><td align="left" valign="top" rowspan="1" colspan="1">154 (56.4)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (30.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Very much</td><td align="left" valign="top" rowspan="1" colspan="1">42 (14.0)</td><td align="left" valign="top" rowspan="1" colspan="1">32 (11.7)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (38.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" colspan="4" align="left" valign="top" rowspan="1">If you consider genetic counseling helpful to you (enough, much, or very much), which is the reason?<xref rid="jgc41630-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Personal reassurance</td><td align="left" valign="top" rowspan="1" colspan="1">48 (16.7)</td><td align="left" valign="top" rowspan="1" colspan="1">40 (15.3)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (32.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Reassurance for family members</td><td align="left" valign="top" rowspan="1" colspan="1">58 (20.2)</td><td align="left" valign="top" rowspan="1" colspan="1">55 (21.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (12.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Personal and family reassurance</td><td align="left" valign="top" rowspan="1" colspan="1">59 (20.6)</td><td align="left" valign="top" rowspan="1" colspan="1">55 (21.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (16.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Cancer is not hereditary</td><td align="left" valign="top" rowspan="1" colspan="1">50 (17.4)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (17.2)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (20.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Therapeutic decisions</td><td align="left" valign="top" rowspan="1" colspan="1">13 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">N.A.</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Cancer prevention</td><td align="left" valign="top" rowspan="1" colspan="1">6 (2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Improvement of personal knowledge</td><td align="left" valign="top" rowspan="1" colspan="1">13 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (4.2)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (8.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">13 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (4.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">27 (9.4)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (9.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">2.4 How would you describe your experience with genetic counseling and <italic toggle="yes">BRCA</italic> testing?</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Negative, it generated stress/concern</td><td align="left" valign="top" rowspan="1" colspan="1">16 (5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (5.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Negative, it was too complicated (waiting times, uncertain results)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Positive, it helped me to make sense to what happened and to plan appropriate preventive measures</td><td align="left" valign="top" rowspan="1" colspan="1">183 (61.2)</td><td align="left" valign="top" rowspan="1" colspan="1">166 (60.8)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (65.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Positive, it had to be done as well as other medical exams</td><td align="left" valign="top" rowspan="1" colspan="1">97 (32.4)</td><td align="left" valign="top" rowspan="1" colspan="1">88 (32.2)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (34.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">2.5 Did you feel uncomfortable because the first contact with our center took place by phone?<xref rid="jgc41630-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not at all</td><td align="left" valign="top" rowspan="1" colspan="1">287 (96.3)</td><td align="left" valign="top" rowspan="1" colspan="1">261 (96.0)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (100.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">A little</td><td align="left" valign="top" rowspan="1" colspan="1">4 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Enough</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Much</td><td align="left" valign="top" rowspan="1" colspan="1">6 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Very much</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" colspan="4" align="left" valign="top" rowspan="1">For which reason did you feel uncomfortable (a little, enough, or much)?</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">To leave my request to an answering machine</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">To talk about my personal condition without facing the person I was talking with</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Understanding what I was asked</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">3.1 What does a normal <italic toggle="yes">BRCA</italic> test mean?</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cancer is certainly not genetic/hereditary</td><td align="left" valign="top" rowspan="1" colspan="1">174 (58.2)</td><td align="left" valign="top" rowspan="1" colspan="1">159 (58.2)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (57.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">There is still a low chance that the cancer is genetic/hereditary</td><td align="left" valign="top" rowspan="1" colspan="1">67 (22.4)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (22.0)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (26.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Don'&#8217;t know</td><td align="left" valign="top" rowspan="1" colspan="1">4 (1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">54 (18.1)</td><td align="left" valign="top" rowspan="1" colspan="1">50 (18.3)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (15.4)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">3.2 What is the life&#8208;time risk of breast cancer in <italic toggle="yes">BRCA</italic> mutation carriers compared to the Italian general population?<xref rid="jgc41630-note-0007" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lower</td><td align="left" valign="top" rowspan="1" colspan="1">5 (1.7)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Equal</td><td align="left" valign="top" rowspan="1" colspan="1">8 (2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Greater</td><td align="left" valign="top" rowspan="1" colspan="1">197 (65.9)</td><td align="left" valign="top" rowspan="1" colspan="1">180 (65.9)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (65.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Don'&#8217;t known</td><td align="left" valign="top" rowspan="1" colspan="1">89 (29.8)</td><td align="left" valign="top" rowspan="1" colspan="1">80 (29.3)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (34.6)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">3.3 What is the life&#8208;time risk of ovarian cancer in <italic toggle="yes">BRCA</italic> mutation carriers compared to the Italian general population?<xref rid="jgc41630-note-0007" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lower</td><td align="left" valign="top" rowspan="1" colspan="1">5 (1.7)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Equal</td><td align="left" valign="top" rowspan="1" colspan="1">5 (1.7)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Greater</td><td align="left" valign="top" rowspan="1" colspan="1">196 (65.6)</td><td align="left" valign="top" rowspan="1" colspan="1">179 (65.6)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (65.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Don'&#8217;t known</td><td align="left" valign="top" rowspan="1" colspan="1">93 (31.1)</td><td align="left" valign="top" rowspan="1" colspan="1">84 (30.8)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (34.6)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">3.4 Do you remember if women carrying <italic toggle="yes">BRCA</italic> mutation have a higher risk of cancers other than breast and ovarian cancers?</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Don'&#8217;t know</td><td align="left" valign="top" rowspan="1" colspan="1">132 (44.1)</td><td align="left" valign="top" rowspan="1" colspan="1">117 (42.9)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (57.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">70 (23.4)</td><td align="left" valign="top" rowspan="1" colspan="1">66 (24.2)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (15.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">95 (31.8)</td><td align="left" valign="top" rowspan="1" colspan="1">88 (32.2)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (26.9)</td></tr><tr><td style="padding-left:10%" colspan="4" align="left" valign="top" rowspan="1">If YES, do you remember which cancers? (several cancer sites could be reported)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Uterus</td><td align="left" valign="top" rowspan="1" colspan="1">25</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Large bowel</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="left" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Lung</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Bone</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Liver</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Pancreas</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">3.5 Do you remember if men carrying <italic toggle="yes">BRCA</italic> mutation have a higher risk of other cancers?</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Don'&#8217;t know</td><td align="left" valign="top" rowspan="1" colspan="1">170 (56.9)</td><td align="left" valign="top" rowspan="1" colspan="1">152 (55.7)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (69.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">12 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">115 (38.5)</td><td align="left" valign="top" rowspan="1" colspan="1">108 (39.6)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (26.9)</td></tr><tr><td style="padding-left:10%" colspan="4" align="left" valign="top" rowspan="1">If YES, do you remember which cancers? (several cancer sites could be reported)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Prostate</td><td align="left" valign="top" rowspan="1" colspan="1">77</td><td align="left" valign="top" rowspan="1" colspan="1">70</td><td align="left" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Breast</td><td align="left" valign="top" rowspan="1" colspan="1">29</td><td align="left" valign="top" rowspan="1" colspan="1">28</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Large bowel</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Lung</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Pancreas</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot id="jgc41630-ntgp-0003"><fn id="jgc41630-note-0004"><p>Abbreviation: N.A., not applicable.</p></fn><fn id="jgc41630-note-0005"><label>
<sup>a</sup>
</label><p>Open answers were categorized after collecting all questionnaires.</p></fn><fn id="jgc41630-note-0006"><label>
<sup>b</sup>
</label><p>A BC patient had genetic counseling immediately.</p></fn><fn id="jgc41630-note-0007"><label>
<sup>c</sup>
</label><p>Reported cancer risks among <italic toggle="yes">BRCA</italic> mutation carriers and the general Italian population were compared to provide a qualitative value (i.e., increased, same, decreased) for each participant.</p></fn></table-wrap-foot></table-wrap><p>Most women (96.3%) did not feel uncomfortable to have their first contact with the UHC by phone. Overall, 289 out of 299 women (96.7%) considered their genetic counseling helpful, and 68.2% considered it much or very much helpful; rates were similar for BC patients and women without BC. Women who considered their genetic counseling helpful (<italic toggle="yes">n</italic>&#160;=&#160;289) were asked to describe which was the most valuable aspect and 165 of them (57.1%) reported they felt reassured for themselves and for their family, with similar rates among BC patients (57.3%) and women without BC (60.0%).</p><p>Overall, 280 of 299 women (93.6%) viewed their experience with genetic counseling and <italic toggle="yes">BRCA</italic> testing positively: 65.3% (<italic toggle="yes">n</italic>&#160;=&#160;183) felt that genetic counseling helped them &#8220;to make sense of what happened and to plan appropriate preventive measures&#8221; while 34.6% (<italic toggle="yes">n</italic>&#160;=&#160;97) considered &#8220;it had to be done as well as other medical exams.&#8221; Similar rates were observed between BC patients and women without BC.</p><p>Based on their <italic toggle="yes">BRCA</italic> test result, only 18&#8201;BC patients reported some changes in their check&#8208;ups or in their relatives' preventive practices. In all cases, changes were reported as paying more attention to cancer secondary prevention. Of the 283 women who reported that they did not change their preventive practice, 177 (62.5%) reported annual breast (Mammography and/or Ultrasound) and gynecological examinations (clinical examination and pap test), five BC patients reported only breast (<italic toggle="yes">n</italic>&#160;=&#160;4) or gynecological (<italic toggle="yes">n</italic>&#160;=&#160;1) cancer surveillance, and 67 (23.7%) women did not report which examinations they usually performed (Table&#160;<xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">S7</xref>).</p></sec><sec id="jgc41630-sec-0018"><label>3.5</label><title>Knowledge</title><p>Answers to the questions investigating knowledge of <italic toggle="yes">BRCA</italic> testing are reported in Table&#160;<xref rid="jgc41630-tbl-0003" ref-type="table">3</xref>.</p><p>When asked to report what, in their opinion, &#8220;normal <italic toggle="yes">BRCA</italic> test result&#8221; means, 174 women (58.2%) answered &#8220;cancer is not hereditary,&#8221; 67 women (22.4%) said &#8220;there is still a low probability of a hereditary syndrome&#8221; and 58 women (19.4%) did not respond or did not know.</p><p>Regarding cancer risks, 66% of women thought that <italic toggle="yes">BRCA</italic> mutation carriers have a greater risk of both BC (65.9%) and OC (65.6%), around one in three did not express an opinion and a few reported no difference or a lower cancer risk in <italic toggle="yes">BRCA</italic> mutation carriers than in the general population. An increased risk of cancers other than BC and OC among women carrying a <italic toggle="yes">BRCA</italic> mutation was reported by 31.8% of women and the most frequently reported cancer sites were the uterus, large bowel, lung, bones, liver, and pancreas.</p><p>A total of 38.5% of women knew that men who carry a <italic toggle="yes">BRCA</italic> mutation have an increased risk of cancer at several sites and the most frequently reported were prostate, breast, and large bowel.</p></sec><sec id="jgc41630-sec-0019"><label>3.6</label><title>
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">BRCA</italic>
</styled-content>&#8208;associated activity of the <styled-content style="fixed-case" toggle="no">UHC</styled-content>
</title><p>During the last 5&#8201;years, the <italic toggle="yes">BRCA</italic>&#8208;associated activity of the UHC increased from 147 tests in 2017 to 668 tests in 2021. Each year, around 90% of the tests were uninformative and of these around 90% were communicated to the patients by phone by a nurse (Table&#160;<xref rid="jgc41630-supitem-0001" ref-type="supplementary-material">S8</xref>). In the near future, more than 700 test/year are expected at our unit. Based on our previous experience, we estimate that we can save around 10&#160;min for each telephone versus in&#8208;person communication, which translates into at least 95&#8201;h of nurse work/year, i.e., 14 working days/year saved.</p></sec></sec><sec sec-type="discussion" id="jgc41630-sec-0020"><label>4</label><title>DISCUSSION</title><p>The results of our study show that women with an uninformative BRCA test result who are not considered to be at high risk due to their personal/family history of cancer have a positive experience with a &#8220;light&#8221; genetic counseling path in which they are only counseled by nurses, and they receive their test result by phone. To our knowledge, this is the first study reporting a nurse&#8208;driven genetic counseling pathway in Italy.</p><p>Overall, we found that almost all women who took part in the study reported a positive experience with the genetic counseling process and the <italic toggle="yes">BRCA</italic> testing, and the majority of them were reassured for themselves and for their family. This suggests that the amount and type of information and the support provided by the nurses were perceived as adequate to meet the needs of the counselees and that a nurse&#8208;driven mostly telephonic genetic counseling pathway is highly acceptable for Italian women with an uninformative <italic toggle="yes">BRCA</italic> test.</p><p>Previous studies comparing the experience of people who had a telephone genetic counseling or traditional in&#8208;person genetic counseling showed similar results in the two groups (McCuaig et al.,&#160;<xref rid="jgc41630-bib-0016" ref-type="bibr">2018</xref>). In particular, two randomized trials showed that phone disclosure of the test result can be a reasonable alternative to traditional in&#8208;person <italic toggle="yes">BRCA</italic> test disclosure without any negative psychologic outcome or compromise in knowledge (Jenkins et al.,&#160;<xref rid="jgc41630-bib-0013" ref-type="bibr">2007</xref>; Kilbride et al.,&#160;<xref rid="jgc41630-bib-0015" ref-type="bibr">2020</xref>). However, Beri et al.&#160;(<xref rid="jgc41630-bib-0002" ref-type="bibr">2019</xref>) reported that some individual characteristics such as age, anxiety, and cancer&#8208;specific distress should be considered when offering an in&#8208;person rather than a telephone test disclosure.</p><p>Most women remembered their <italic toggle="yes">BRCA</italic> result and correctly defined it as &#8220;negative/normal.&#8221; Also, the majority of women retained correct information on the clinical implications of the test result and stated that after genetic counseling they did not change their BC or OC prevention exams that were consistent with the indications for secondary prevention in our country. In addition, the majority of women reported that they shared the test result with their family members. So, we can assume that the nurses in the post&#8208;test telephonic consultation provided information (and counseling) that effectively clarified the clinical implication of an uninformative test result and highlighted the importance of familial communication. However, a randomized study (Kilbride et al.,&#160;<xref rid="jgc41630-bib-0015" ref-type="bibr">2020</xref>) reported lower adherence to medical follow&#8208;up among subjects who had a telephone disclosure of the test result as compared to those who had an in&#8208;person disclosure.</p><p>Around three out of five women considered the absence of a <italic toggle="yes">BRCA</italic> mutation as clear&#8208;cut evidence of the absence of hereditary cancer, one in five did not answer the question and only one in five correctly considered the limits of the test and indicated that a low probability of HBOC remains. Although it is expected that few additional hereditary situations are present within this group of individuals, this finding suggests that the complexity of the interpretation of a personal/family history of BC/OC cancer in the presence of an uninformative <italic toggle="yes">BRCA</italic> test was not fully understood by the majority of the women. Perhaps, nurses gave more prominence to the good part of the message (no pathogenic variant) than to the gray part (hereditary cancer cannot be excluded), with the intent to reassure these women. However, the explanatory letter sent with the laboratory report clearly stated that hereditary cancer could not be excluded due to the limits of the test and that a new contact with the service is suggested if the personal/family history were to change in the future as the present evaluation may also change based on the new findings. Further research is needed on this aspect because a &#8220;black or white&#8221; understanding of the <italic toggle="yes">BRCA</italic> test result may be harmful if these women were not taking action on additional genetic testing in the future based on this wrong interpretation of the uninformative <italic toggle="yes">BRCA</italic> test result.</p><p>Among interviewed women, knowledge of cancer risk associated with <italic toggle="yes">BRCA</italic> was limited as only 66% of women recalled that <italic toggle="yes">BRCA</italic> mutation carriers have a greater risk of both breast and ovarian cancers than women of the general population. Although this might be partly due to reasons not related to the genetic counseling content (e.g., women may not be interested in retaining information that did not apply to them and/or found it difficult to remember cancer risks during the telephone survey), these finding questions the cancer risk educational content of genetic counseling provided to these women. Education about cancer risk figures was indeed not considered a priority (e.g., it was not discussed during the weekly staff meeting, specific information material was not used) and should be improved. However, communicating about genetic testing and cancer risk is a complex task and limited evidence is available to guide practice (Jacobs et al.,&#160;<xref rid="jgc41630-bib-0012" ref-type="bibr">2019</xref>).</p><p>From a service&#8208;centered point of view, our model seems to be efficient in terms of saving staff time. Given the growing number of tests managed, even a small difference in time saved between a telephone and an in&#8208;person communication has a significant impact (around 2&#8201;weeks of working time of oncology nurses in year 2021). Moreover, this model reduces the need for medical offices dedicated to an in&#8208;person counseling session. From a patient&#8208;centered perspective, women save time and inconvenience of going to the UHC for an in&#8208;person session. A study carried out in Australia involving women with OC who were counseled by telephone showed that participants were highly satisfied with telephone interactions with the genetics counselors and the service was found to be cost&#8208;effective (Tutty et al.,&#160;<xref rid="jgc41630-bib-0025" ref-type="bibr">2019</xref>).</p><p>The need of mainstreaming genetics in cancer practice supports the need for increased competence in the genetics of all health professionals within an oncology team to allow a proper care relationship with patients undergoing genetic testing. In this scenario, oncology nurses may play an important role as they have been trained to care for the psychosocial needs of these patients. After training in cancer genetics, this expertise can be used to manage the issues involved in a &#8220;light&#8221; genetic counseling pathway where no major genetic complexities have to be dealt with.</p><p>Evidence for nurse&#8208;led cancer genetic testing in the medical literature is minimal but concordant in showing the benefit of this model. The Mainstreaming Cancer Genetics (MCG) program carried out at the Royal Marsden Hospital piloted in routine ovarian cancer clinical practice a new <italic toggle="yes">BRCA</italic> testing pathway in which the trained oncology team directly consents patients for genetic testing and is involved in test result communication while the genetics team is mainly involved in cascade testing to relatives. This model was found to be robust, patient&#8208;centered, and cost&#8208;effective (George et al.,&#160;<xref rid="jgc41630-bib-0009" ref-type="bibr">2016</xref>). Clinical nurse specialists were also involved in such a program as members of the oncology team: feedback from oncology nurses and patients was encouraging with no significant issues raised in the counseling and consenting process (Percival et al.,&#160;<xref rid="jgc41630-bib-0018" ref-type="bibr">2016</xref>). In the Nottingham University Hospitals&#8217; experience carried out in the Breast clinic, nongenetic nurses with a focused training on <italic toggle="yes">BRCA</italic> testing conduct a <italic toggle="yes">BRCA</italic> testing path, under genetics specialist supervision (Scott et al.,&#160;<xref rid="jgc41630-bib-0021" ref-type="bibr">2020</xref>). Compared with previous referral pathways, the new practice reduced waiting times for all phases of the genetic counseling path. In addition, although formal study data on patient satisfaction was not collected routinely, the authors state that informal data revealed that patients were happy with the service they received.</p><p>Our study has several limits. The nurse&#8208;driven practice was implemented to offer <italic toggle="yes">BRCA</italic> testing to all referred individuals who may benefit from it in a reasonable time frame, as equity of service provision was considered a priority. Unfortunately, pressed by the urgency, we could not evaluate this practice within a proper interventional study. Therefore, we have several weaknesses in interpreting our results. First, we cannot compare the experience and retention of genetic counseling content of our study population with the ones of women who had a traditional in&#8208;person genetic counseling process at our unit. Second, we could not use an established measure of patient satisfaction or knowledge as we did not retrieve a validated Italian version of the scales reported in the literature (e.g., the Genetic Counseling Satisfaction Scale, [DeMarco et al.,&#160;<xref rid="jgc41630-bib-0007" ref-type="bibr">2004</xref>]). In addition, as we did not pilot our questionnaire with the target population, we lost the possibility to identify ambiguities of the questions and misinterpretations. Therefore, our results need to be confirmed by additional studies as the reliability and validity of the instrument we used are unknown. Third, we interviewed the women at least 1 year after the <italic toggle="yes">BRCA</italic> test result in telephone communication, and this may have affected women's remembrance of their experience with the genetic counseling pathway and of the information content. Also, the questionnaire was administered by the UHC nurses and, in 30% of cases, the interviewing nurse was the same who communicated the test result: this may have influenced women's answers. More importantly, it is difficult to generalize the results of this study to our country as in Italy education and training in the genetics of nurses working in genetic units embedded in oncology departments is generally achieved by local in&#8208;house teaching, with a foreseen high variability in the training contents and in the acquired competencies. Finally, the positive experience of the women could be related to the test result (i.e., no pathogenic variant), regardless of the genetic counseling pathway they followed.</p></sec><sec sec-type="conclusions" id="jgc41630-sec-0021"><label>5</label><title>CONCLUSIONS</title><p>This study indicates that a <italic toggle="yes">BRCA</italic> testing process in which nurses with focused expertise carry out both the pretest and post&#8208;test genetic counseling, under the supervision of a geneticist, is suitable for patients who do not carry a pathogenic or likely pathogenic <italic toggle="yes">BRCA</italic> variant as it is associated with a positive patient experience and an adequate retention of implications of the test result, particularly for cancer prevention. As these individuals will represent the vast majority of those entering a <italic toggle="yes">BRCA</italic> testing process in future practice, the design and implementation of models including nurse&#8208;driven &#8220;light&#8221; pathways may contribute to efficient and timely access to <italic toggle="yes">BRCA</italic> genetic testing for cancer patients, leaving health professionals with major expertise in cancer genetics directly involved with the care of patients dealing with a positive <italic toggle="yes">BRCA</italic> test or facing more complex genetic issues.</p></sec><sec id="jgc41630-sec-0028"><title>AUTHOR CONTRIBUTIONS</title><p>EB, LV and LB had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All the authors gave final approval of this version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></sec><sec id="jgc41630-sec-0023"><title>FUNDING INFORMATION</title><p>This work was supported by grants from the Italian Ministry of Health (Ricerca Corrente). The funders and sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p></sec><sec id="jgc41630-sec-0024"><title>COMPLIANCE WITH ETHICAL STANDARDS</title><sec sec-type="COI-statement" id="jgc41630-sec-1024"><title>CONFLICT OF INTEREST</title><p>ML acted as a consultant for Roche, AstraZeneca, Eli Lilly, Exact Sciences, and Novartis and received speaker honoraria from Roche, Sandoz, Takeda, Pfizer, Eli Lilly, Ipsen, and Novartis outside the submitted work. GB reported speaker honoraria from Novartis, Eli Lilly, and Pfizer and had an advisory role for Novartis outside the submitted work. LDM received honoraria from Roche, Novartis, Eli Lilly, MSD Pfizer, Ipsen, AstraZeneca, Genomic Health, Eisai, Pierre Fabre, Daiichi Sankyo, and Seagen and received nonfinancial support from Roche, Pfizer, and Eisai outside the submitted work. All the other authors declare no conflict of interest.</p></sec></sec><sec id="jgc41630-sec-0027"><title>HUMAN STUDIES AND INFORMED CONSENT</title><p>No specific ethical approval was required for this survey as, by providing written consent for the inclusion in the Ligurian <italic toggle="yes">BRCA</italic> registry, individuals accepted to be contacted for an update on personal history, prevention programs, and psychosocial evaluations. The Ligurian <italic toggle="yes">BRCA</italic> registry was approved by the Ligurian Ethics Committee (approval n. 002REG2017).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jgc41630-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Tables S1&#8211;S8</bold>: Ligurian <italic toggle="yes">BRCA</italic> Registry description.</p><p>
<bold>Data S1</bold>: Standard letter sent to patients who had a test result showing no <italic toggle="yes">BRCA</italic> variant.</p><p>
<bold>Data S2</bold>: Standard letter sent to patients carrying a variant of uncertain significance.</p><p>
<bold>Data S3</bold>: Questionnaire.</p><p>
<bold>Data S4</bold>: Categorization of open answers.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JGC4-32-140-s001.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jgc41630-sec-0022"><title>ACKNOWLEDGEMENTS</title><p>ML also acknowledges the support from the Associazione Italiana per la Ricerca sul Cancro (AIRC; grant number MFAG 2020 ID 24698) and the Italian Ministry of Health &#8211; 5&#8201;&#215;&#8201;1000 funds 2017 (no grant number) for pursuing his research efforts in the field of oncofertility. Jehannine Austin served as Action Editor on this manuscript. Open access funding provided by BIBLIOSAN.</p></ack><sec sec-type="data-availability" id="jgc41630-sec-0026"><title>DATA SHARING AND DATA AVAILABILITY</title><p>The data underlying this article will be shared upon reasonable request to the corresponding author.</p></sec><ref-list content-type="cited-references" id="jgc41630-bibl-0001"><title>REFERENCES</title><ref id="jgc41630-bib-0001"><mixed-citation publication-type="journal" id="jgc41630-cit-0001"><string-name name-style="western"><surname>Abacan</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Alsubaie</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Barlow&#8208;Stewart</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Caanen</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Cordier</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Courtney</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Davoine</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Elackatt</surname>, <given-names>N. J.</given-names></string-name>, <string-name name-style="western"><surname>Gardiner</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname>, <given-names>L. H.</given-names></string-name>, <string-name name-style="western"><surname>Malmgren</surname>, <given-names>C. I.</given-names></string-name>, <string-name name-style="western"><surname>Kejriwal</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname>, <given-names>H. J.</given-names></string-name>, <string-name name-style="western"><surname>Lambert</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Lantigua&#8208;Cruz</surname>, <given-names>P. A.</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>, <given-names>J. M. H.</given-names></string-name>, <string-name name-style="western"><surname>Lodahl</surname>, <given-names>M.</given-names></string-name>, &#8230; <string-name name-style="western"><surname>Wicklund</surname>, <given-names>C.</given-names></string-name> (<year>2019</year>). <article-title>The global state of the genetic counseling profession</article-title>. <source>European Journal of Human Genetics</source>, <volume>27</volume>(<issue>2</issue>), <fpage>183</fpage>&#8211;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1038/s41431-018-0252-x</pub-id><pub-id pub-id-type="pmid">30291341</pub-id><pub-id pub-id-type="pmcid">PMC6336871</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0002"><mixed-citation publication-type="journal" id="jgc41630-cit-0002"><string-name name-style="western"><surname>Beri</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Patrick&#8208;Miller</surname>, <given-names>L. J.</given-names></string-name>, <string-name name-style="western"><surname>Egleston</surname>, <given-names>B. L.</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname>, <given-names>M. J.</given-names></string-name>, <string-name name-style="western"><surname>Domchek</surname>, <given-names>S. M.</given-names></string-name>, <string-name name-style="western"><surname>Daly</surname>, <given-names>M. B.</given-names></string-name>, <string-name name-style="western"><surname>Ganschow</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Grana</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Olopade</surname>, <given-names>O. I.</given-names></string-name>, <string-name name-style="western"><surname>Fetzer</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Brandt</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Chambers</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname>, <given-names>D. F.</given-names></string-name>, <string-name name-style="western"><surname>Forman</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Gaber</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Gulden</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Horte</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Long</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Lucas</surname>, <given-names>T.</given-names></string-name>, &#8230; <string-name name-style="western"><surname>Bradbury</surname>, <given-names>A. R.</given-names></string-name> (<year>2019</year>). <article-title>Preferences for in&#8208;person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter communication of GENetic test results by telephone study</article-title>. <source>Clinical Genetics</source>, <volume>95</volume>(<issue>2</issue>), <fpage>293</fpage>&#8211;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1111/cge.13474</pub-id><pub-id pub-id-type="pmid">30417332</pub-id><pub-id pub-id-type="pmcid">PMC6453119</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0003"><mixed-citation publication-type="journal" id="jgc41630-cit-0003"><string-name name-style="western"><surname>Bonelli</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Valle</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Rebora</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Ricci</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Biocchi</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Bruschi</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Parodi</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Bruzzone</surname>, <given-names>C.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Varesco</surname>, <given-names>L.</given-names></string-name> (<year>2021</year>). <article-title>Identification of women at risk of hereditary breast&#8208;ovarian cancer among participants in a population&#8208;based breast cancer screening</article-title>. <source>Familial Cancer</source>, <volume>21</volume>, <fpage>309</fpage>&#8211;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1007/s10689-021-00281-x</pub-id><pub-id pub-id-type="pmid">34669096</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0004"><mixed-citation publication-type="journal" id="jgc41630-cit-0004"><string-name name-style="western"><surname>Buchanan</surname>, <given-names>A. H.</given-names></string-name>, <string-name name-style="western"><surname>Rahm</surname>, <given-names>A. K.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Williams</surname>, <given-names>J. L.</given-names></string-name> (<year>2016</year>). <article-title>Alternate service delivery models in cancer genetic counseling: A mini&#8208;review</article-title>. <source>Frontiers in Oncology</source>, <volume>6</volume>, <fpage>120</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2016.00120</pub-id><pub-id pub-id-type="pmid">27242960</pub-id><pub-id pub-id-type="pmcid">PMC4865495</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0005"><mixed-citation publication-type="journal" id="jgc41630-cit-0005"><string-name name-style="western"><surname>Buchtel</surname>, <given-names>K. M.</given-names></string-name>, <string-name name-style="western"><surname>Vogel Postula</surname>, <given-names>K. J.</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Pineda</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Weissman</surname>, <given-names>S. M.</given-names></string-name> (<year>2018</year>). <article-title>FDA approval of PARP inhibitors and the impact on genetic counseling and genetic testing practices</article-title>. <source>Journal of Genetic Counseling</source>, <volume>27</volume>(<issue>1</issue>), <fpage>131</fpage>&#8211;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1007/s10897-017-0130-7</pub-id><pub-id pub-id-type="pmid">28780754</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0006"><mixed-citation publication-type="journal" id="jgc41630-cit-0006"><string-name name-style="western"><surname>Contegiacomo</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Pensabene</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Capuano</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Tauchmanova</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Federico</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Turchetti</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Cortesi</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Marchetti</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Ricevuto</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Cianci</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Venuta</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Barbieri</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Silingardi</surname>, <given-names>V.</given-names></string-name>, &amp; <collab collab-type="authors">Italian Network on Hereditary Breast Cancer</collab>
. (<year>2004</year>). <article-title>An oncologist&#8208;based model of cancer genetic counselling for hereditary breast and ovarian cancer</article-title>. <source>Annals of Oncology</source>, <volume>15</volume>(<issue>5</issue>), <fpage>726</fpage>&#8211;<lpage>732</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdh183</pub-id><pub-id pub-id-type="pmid">15111339</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0007"><mixed-citation publication-type="journal" id="jgc41630-cit-0007"><string-name name-style="western"><surname>DeMarco</surname>, <given-names>T. A.</given-names></string-name>, <string-name name-style="western"><surname>Peshkin</surname>, <given-names>B. N.</given-names></string-name>, <string-name name-style="western"><surname>Mars</surname>, <given-names>B. D.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Tercyak</surname>, <given-names>K. P.</given-names></string-name> (<year>2004</year>). <article-title>Patient satisfaction with cancer genetic counseling: A psychometric analysis of the genetic counseling satisfaction scale</article-title>. <source>Journal of Genetic Counseling</source>, <volume>13</volume>(<issue>4</issue>), <fpage>293</fpage>&#8211;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1023/B:JOGC.0000035523.96133.bc</pub-id><pub-id pub-id-type="pmid">19736695</pub-id><pub-id pub-id-type="pmcid">PMC3551590</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0008"><mixed-citation publication-type="journal" id="jgc41630-cit-0008"><string-name name-style="western"><surname>Domchek</surname>, <given-names>S. M.</given-names></string-name> (<year>2019</year>). <article-title>Risk&#8208;reducing mastectomy in <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> mutation carriers: A complex discussion</article-title>. <source>JAMA</source>, <volume>321</volume>(<issue>1</issue>), <fpage>27</fpage>. <pub-id pub-id-type="doi">10.1001/jama.2018.18942</pub-id><pub-id pub-id-type="pmid">30521006</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0009"><mixed-citation publication-type="journal" id="jgc41630-cit-0009"><string-name name-style="western"><surname>George</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Riddell</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Seal</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Talukdar</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Mahamdallie</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Ruark</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Cloke</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Slade</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Kemp</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Gore</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Strydom</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Banerjee</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Hanson</surname>, <given-names>H.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Rahman</surname>, <given-names>N.</given-names></string-name> (<year>2016</year>). <article-title>Implementing rapid, robust, cost&#8208;effective, patient&#8208;centred, routine genetic testing in ovarian cancer patients</article-title>. <source>Scientific Reports</source>, <volume>6</volume>(<issue>1</issue>), <elocation-id>29506</elocation-id>. <pub-id pub-id-type="doi">10.1038/srep29506</pub-id><pub-id pub-id-type="pmid">27406733</pub-id><pub-id pub-id-type="pmcid">PMC4942815</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0010"><mixed-citation publication-type="journal" id="jgc41630-cit-0010"><string-name name-style="western"><surname>Gori</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Barberis</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Bella</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><surname>Buttitta</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Capoluongo</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Carrera</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Colombo</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Cortesi</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Genuardi</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Gion</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Guarneri</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Incorvaia</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>la Verde</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Lorusso</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Marchetti</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Marchetti</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Normanno</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Pasini</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Pensabene</surname>, <given-names>M.</given-names></string-name>, &#8230; <string-name name-style="western"><surname>Russo</surname>, <given-names>A.</given-names></string-name> (<year>2019</year>). <article-title>Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives</article-title>. <source>Critical Reviews in Oncology/Hematology</source>, <volume>140</volume>, <fpage>67</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2019.05.012</pub-id><pub-id pub-id-type="pmid">31176273</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0011"><mixed-citation publication-type="journal" id="jgc41630-cit-0011"><string-name name-style="western"><surname>Hoogerbrugge</surname>, <given-names>N.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Jongmans</surname>, <given-names>M. C.</given-names></string-name> (<year>2016</year>). <article-title>Finding all BRCA pathogenic mutation carriers: Best practice models</article-title>. <source>European Journal of Human Genetics</source>, <volume>24</volume>(<issue>S1</issue>), <fpage>S19</fpage>&#8211;<lpage>S26</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2016.95</pub-id><pub-id pub-id-type="pmid">27514840</pub-id><pub-id pub-id-type="pmcid">PMC5141577</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0012"><mixed-citation publication-type="journal" id="jgc41630-cit-0012"><string-name name-style="western"><surname>Jacobs</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Patch</surname>, <given-names>C.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Michie</surname>, <given-names>S.</given-names></string-name> (<year>2019</year>). <article-title>Communication about genetic testing with breast and ovarian cancer patients: A scoping review</article-title>. <source>European Journal of Human Genetics</source>, <volume>27</volume>(<issue>4</issue>), <fpage>511</fpage>&#8211;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1038/s41431-018-0310-4</pub-id><pub-id pub-id-type="pmid">30573802</pub-id><pub-id pub-id-type="pmcid">PMC6460583</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0013"><mixed-citation publication-type="journal" id="jgc41630-cit-0013"><string-name name-style="western"><surname>Jenkins</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Calzone</surname>, <given-names>K. A.</given-names></string-name>, <string-name name-style="western"><surname>Dimond</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Liewehr</surname>, <given-names>D. J.</given-names></string-name>, <string-name name-style="western"><surname>Steinberg</surname>, <given-names>S. M.</given-names></string-name>, <string-name name-style="western"><surname>Jourkiv</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Soballe</surname>, <given-names>P. W.</given-names></string-name>, <string-name name-style="western"><surname>Prindiville</surname>, <given-names>S. A.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Kirsch</surname>, <given-names>I. R.</given-names></string-name> (<year>2007</year>). <article-title>Randomized comparison of phone versus in&#8208;person BRCA1/2 predisposition genetic test result disclosure counseling</article-title>. <source>Genetics in Medicine</source>, <volume>9</volume>(<issue>8</issue>), <fpage>487</fpage>&#8211;<lpage>495</lpage>. <pub-id pub-id-type="doi">10.1097/GIM.0b013e31812e6220</pub-id><pub-id pub-id-type="pmid">17700386</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0014"><mixed-citation publication-type="journal" id="jgc41630-cit-0014"><string-name name-style="western"><surname>Kentwell</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Dow</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Antill</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Wrede</surname>, <given-names>C. D.</given-names></string-name>, <string-name name-style="western"><surname>McNally</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><surname>Higgs</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Hamilton</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Ananda</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Lindeman</surname>, <given-names>G. J.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Scott</surname>, <given-names>C. L.</given-names></string-name> (<year>2017</year>). <article-title>Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics</article-title>. <source>Gynecologic Oncology</source>, <volume>145</volume>(<issue>1</issue>), <fpage>130</fpage>&#8211;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2017.01.030</pub-id><pub-id pub-id-type="pmid">28162234</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0015"><mixed-citation publication-type="journal" id="jgc41630-cit-0015"><string-name name-style="western"><surname>Kilbride</surname>, <given-names>M. K.</given-names></string-name>, <string-name name-style="western"><surname>Egleston</surname>, <given-names>B. L.</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname>, <given-names>M. J.</given-names></string-name>, <string-name name-style="western"><surname>Patrick&#8208;Miller</surname>, <given-names>L. J.</given-names></string-name>, <string-name name-style="western"><surname>Daly</surname>, <given-names>M. B.</given-names></string-name>, <string-name name-style="western"><surname>Ganschow</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Grana</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Olopade</surname>, <given-names>O. I.</given-names></string-name>, <string-name name-style="western"><surname>Fetzer</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Brandt</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Chambers</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname>, <given-names>D. F.</given-names></string-name>, <string-name name-style="western"><surname>Forman</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Gaber</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Gulden</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Horte</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Long</surname>, <given-names>J. M.</given-names></string-name>, <string-name name-style="western"><surname>Lucas</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Madaan</surname>, <given-names>S.</given-names></string-name>, &#8230; <string-name name-style="western"><surname>Bradbury</surname>, <given-names>A. R.</given-names></string-name> (<year>2020</year>). <article-title>Longitudinal follow&#8208;up after telephone disclosure in the randomized COGENT study</article-title>. <source>Genetics in Medicine</source>, <volume>22</volume>(<issue>8</issue>), <fpage>1401</fpage>&#8211;<lpage>1406</lpage>. <pub-id pub-id-type="doi">10.1038/s41436-020-0808-3</pub-id><pub-id pub-id-type="pmid">32376981</pub-id><pub-id pub-id-type="pmcid">PMC7396300</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0016"><mixed-citation publication-type="journal" id="jgc41630-cit-0016"><string-name name-style="western"><surname>McCuaig</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Armel</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Care</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Volenik</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname>, <given-names>R.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Metcalfe</surname>, <given-names>K.</given-names></string-name> (<year>2018</year>). <article-title>Next&#8208;generation service delivery: A scoping review of patient outcomes associated with alternative models of genetic counseling and genetic testing for hereditary cancer</article-title>. <source>Cancers</source>, <volume>10</volume>(<issue>11</issue>), <elocation-id>435</elocation-id>. <pub-id pub-id-type="doi">10.3390/cancers10110435</pub-id><pub-id pub-id-type="pmid">30428547</pub-id><pub-id pub-id-type="pmcid">PMC6266465</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0017"><mixed-citation publication-type="journal" id="jgc41630-cit-0017"><string-name name-style="western"><surname>Ormond</surname>, <given-names>K. E.</given-names></string-name>, <string-name name-style="western"><surname>Laurino</surname>, <given-names>M. Y.</given-names></string-name>, <string-name name-style="western"><surname>Barlow&#8208;Stewart</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Wessels</surname>, <given-names>T.&#8208;M.</given-names></string-name>, <string-name name-style="western"><surname>Macaulay</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Austin</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Middleton</surname>, <given-names>A.</given-names></string-name> (<year>2018</year>). <article-title>Genetic counseling globally: Where are we now?</article-title><source>American Journal of Medical Genetics. Part C, Seminars in Medical Genetics</source>, <volume>178</volume>(<issue>1</issue>), <fpage>98</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.c.31607</pub-id><pub-id pub-id-type="pmid">29575600</pub-id><pub-id pub-id-type="pmcid">PMC5947883</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0018"><mixed-citation publication-type="journal" id="jgc41630-cit-0018"><string-name name-style="western"><surname>Percival</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>George</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Gyertson</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Hamill</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Fernandes</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Rahman</surname>, <given-names>N.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Banerjee</surname>, <given-names>S.</given-names></string-name> (<year>2016</year>). <article-title>The integration of BRCA testing into oncology clinics</article-title>. <source>British Journal of Nursing</source>, <volume>25</volume>(<issue>12</issue>), <fpage>690</fpage>&#8211;<lpage>694</lpage>. <pub-id pub-id-type="doi">10.12968/bjon.2016.25.12.690</pub-id><pub-id pub-id-type="pmid">27345073</pub-id><pub-id pub-id-type="pmcid">PMC5993185</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0019"><mixed-citation publication-type="journal" id="jgc41630-cit-0019"><string-name name-style="western"><surname>Raphael</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Hewitt</surname>, <given-names>P.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Eisen</surname>, <given-names>A.</given-names></string-name> (<year>2016</year>). <article-title>The impact of Angelina Jolie (AJ)&#8217;s story on genetic referral and testing at an academic cancer Centre in Canada</article-title>. <source>Journal of Genetic Counseling</source>, <volume>25</volume>(<issue>6</issue>), <fpage>1309</fpage>&#8211;<lpage>1316</lpage>. <pub-id pub-id-type="doi">10.1007/s10897-016-9973-6</pub-id><pub-id pub-id-type="pmid">27228984</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0020"><mixed-citation publication-type="journal" id="jgc41630-cit-0020"><string-name name-style="western"><surname>Robson</surname>, <given-names>M. E.</given-names></string-name>, <string-name name-style="western"><surname>Bradbury</surname>, <given-names>A. R.</given-names></string-name>, <string-name name-style="western"><surname>Arun</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Domchek</surname>, <given-names>S. M.</given-names></string-name>, <string-name name-style="western"><surname>Ford</surname>, <given-names>J. M.</given-names></string-name>, <string-name name-style="western"><surname>Hampel</surname>, <given-names>H. L.</given-names></string-name>, <string-name name-style="western"><surname>Lipkin</surname>, <given-names>S. M.</given-names></string-name>, <string-name name-style="western"><surname>Syngal</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Wollins</surname>, <given-names>D. S.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Lindor</surname>, <given-names>N. M.</given-names></string-name> (<year>2015</year>). <article-title>American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility</article-title>. <source>Journal of Clinical Oncology</source>, <volume>33</volume>(<issue>31</issue>), <fpage>3660</fpage>&#8211;<lpage>3667</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2015.63.0996</pub-id><pub-id pub-id-type="pmid">26324357</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0021"><mixed-citation publication-type="journal" id="jgc41630-cit-0021"><string-name name-style="western"><surname>Scott</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>O'Sullivan</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Asgeirsson</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Macmillan</surname>, <given-names>D.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Wilson</surname>, <given-names>E.</given-names></string-name> (<year>2020</year>). <article-title>Changing practice: Moving to a specialist nurse&#8208;led service for BRCA gene testing</article-title>. <source>British Journal of Nursing</source>, <volume>29</volume>(<issue>10</issue>), <fpage>S6</fpage>&#8211;<lpage>S13</lpage>. <pub-id pub-id-type="doi">10.12968/bjon.2020.29.10.S6</pub-id><pub-id pub-id-type="pmid">32463748</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0022"><mixed-citation publication-type="journal" id="jgc41630-cit-0022"><string-name name-style="western"><surname>Skirton</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Kerzin&#8208;Storrar</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Longmuir</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Patch</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname>, <given-names>G.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Walford&#8208;Moore</surname>, <given-names>J.</given-names></string-name> (<year>2013</year>). <article-title>Building the genetic counsellor profession in the United Kingdom: Two decades of growth and development</article-title>. <source>Journal of Genetic Counseling</source>, <volume>22</volume>(<issue>6</issue>), <fpage>902</fpage>&#8211;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1007/s10897-012-9560-4</pub-id><pub-id pub-id-type="pmid">23334530</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0023"><mixed-citation publication-type="journal" id="jgc41630-cit-0023"><string-name name-style="western"><surname>Trepanier</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Ahrens</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>McKinnon</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><surname>Peters</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Stopfer</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Grumet</surname>, <given-names>S. C.</given-names></string-name>, <string-name name-style="western"><surname>Manley</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Culver</surname>, <given-names>J. O.</given-names></string-name>, <string-name name-style="western"><surname>Acton</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Larsen&#8208;Haidle</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Correia</surname>, <given-names>L. A.</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Pettersen</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Ferlita</surname>, <given-names>T. D.</given-names></string-name>, <string-name name-style="western"><surname>Costalas</surname>, <given-names>J. W.</given-names></string-name>, <string-name name-style="western"><surname>Hunt</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Donlon</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Skrzynia</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Farrell</surname>, <given-names>C.</given-names></string-name>, &#8230; <collab collab-type="authors">National Society of Genetic Counselors</collab>
. (<year>2004</year>). <article-title>Genetic cancer risk assessment and counseling: Recommendations of the National Society of genetic counselors</article-title>. <source>Journal of Genetic Counseling</source>, <volume>13</volume>(<issue>2</issue>), <fpage>83</fpage>&#8211;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1023/B:JOGC.0000018821.48330.77</pub-id><pub-id pub-id-type="pmid">15604628</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0024"><mixed-citation publication-type="journal" id="jgc41630-cit-0024"><string-name name-style="western"><surname>Tutt</surname>, <given-names>A. N. J.</given-names></string-name>, <string-name name-style="western"><surname>Garber</surname>, <given-names>J. E.</given-names></string-name>, <string-name name-style="western"><surname>Kaufman</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Viale</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Fumagalli</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Rastogi</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Gelber</surname>, <given-names>R. D.</given-names></string-name>, <string-name name-style="western"><surname>de Azambuja</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Fielding</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Balma&#241;a</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Domchek</surname>, <given-names>S. M.</given-names></string-name>, <string-name name-style="western"><surname>Gelmon</surname>, <given-names>K. A.</given-names></string-name>, <string-name name-style="western"><surname>Hollingsworth</surname>, <given-names>S. J.</given-names></string-name>, <string-name name-style="western"><surname>Korde</surname>, <given-names>L. A.</given-names></string-name>, <string-name name-style="western"><surname>Linderholm</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Bandos</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Senkus</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Suga</surname>, <given-names>J. M.</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname>, <given-names>Z.</given-names></string-name>, &#8230; <collab collab-type="authors">OlympiA Clinical Trial Steering Committee and Investigators</collab>
. (<year>2021</year>). <article-title>Adjuvant Olaparib for patients with <italic toggle="yes">BRCA1</italic>&#8208; or <italic toggle="yes">BRCA2</italic>&#8208;mutated breast cancer</article-title>. <source>New England Journal of Medicine</source>, <volume>384</volume>, <fpage>2394</fpage>&#8211;<lpage>2405</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2105215</pub-id><pub-id pub-id-type="pmid">34081848</pub-id><pub-id pub-id-type="pmcid">PMC9126186</pub-id></mixed-citation></ref><ref id="jgc41630-bib-0025"><mixed-citation publication-type="journal" id="jgc41630-cit-0025"><string-name name-style="western"><surname>Tutty</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Petelin</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>McKinley</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Young</surname>, <given-names>M.&#8208;A.</given-names></string-name>, <string-name name-style="western"><surname>Meiser</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Rasmussen</surname>, <given-names>V. M.</given-names></string-name>, <string-name name-style="western"><surname>Forbes Shepherd</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>James</surname>, <given-names>P. A.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Forrest</surname>, <given-names>L. E.</given-names></string-name> (<year>2019</year>). <article-title>Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high&#8208;grade serous ovarian cancer</article-title>. <source>European Journal of Human Genetics</source>, <volume>27</volume>(<issue>8</issue>), <fpage>1186</fpage>&#8211;<lpage>1196</lpage>. <pub-id pub-id-type="doi">10.1038/s41431-019-0390-9</pub-id><pub-id pub-id-type="pmid">30962500</pub-id><pub-id pub-id-type="pmcid">PMC6777607</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>